全文获取类型
收费全文 | 1545317篇 |
免费 | 99413篇 |
国内免费 | 3566篇 |
专业分类
耳鼻咽喉 | 22643篇 |
儿科学 | 47435篇 |
妇产科学 | 44462篇 |
基础医学 | 214730篇 |
口腔科学 | 46055篇 |
临床医学 | 128849篇 |
内科学 | 302997篇 |
皮肤病学 | 34912篇 |
神经病学 | 120171篇 |
特种医学 | 63664篇 |
外国民族医学 | 523篇 |
外科学 | 238103篇 |
综合类 | 32310篇 |
现状与发展 | 6篇 |
一般理论 | 454篇 |
预防医学 | 111325篇 |
眼科学 | 35887篇 |
药学 | 114092篇 |
6篇 | |
中国医学 | 3285篇 |
肿瘤学 | 86387篇 |
出版年
2018年 | 16703篇 |
2017年 | 14150篇 |
2016年 | 14448篇 |
2015年 | 17315篇 |
2014年 | 22198篇 |
2013年 | 30579篇 |
2012年 | 44968篇 |
2011年 | 42551篇 |
2010年 | 24747篇 |
2009年 | 25392篇 |
2008年 | 38386篇 |
2007年 | 42116篇 |
2006年 | 42733篇 |
2005年 | 48987篇 |
2004年 | 49215篇 |
2003年 | 43917篇 |
2002年 | 38914篇 |
2001年 | 67726篇 |
2000年 | 67795篇 |
1999年 | 60259篇 |
1998年 | 15519篇 |
1997年 | 13957篇 |
1996年 | 13477篇 |
1995年 | 12727篇 |
1992年 | 48029篇 |
1991年 | 46722篇 |
1990年 | 46193篇 |
1989年 | 44921篇 |
1988年 | 41906篇 |
1987年 | 41318篇 |
1986年 | 39546篇 |
1985年 | 37178篇 |
1984年 | 27681篇 |
1983年 | 23347篇 |
1982年 | 13501篇 |
1981年 | 12225篇 |
1979年 | 26924篇 |
1978年 | 18971篇 |
1977年 | 16241篇 |
1976年 | 14710篇 |
1975年 | 17271篇 |
1974年 | 20633篇 |
1973年 | 19847篇 |
1972年 | 19045篇 |
1971年 | 18058篇 |
1970年 | 17077篇 |
1969年 | 16430篇 |
1968年 | 15410篇 |
1967年 | 13916篇 |
1966年 | 12954篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
5.
Improvement in Tricuspid Annular Plane Systolic Excursion with Pulmonary Hypertension Therapy in Pediatric Patients 下载免费PDF全文
6.
7.
8.
9.
10.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献